Please upgrade your browser.
Give STL Day is an online national day of giving to the community, organized by the local Greater St. Louis Community Foundation. On May 5, you can go to https://www.givestlday.org/#npo/bialeckikidney-cancer-foundation and designate, easily and safely, your gift to the Bialecki Kidney Cancer Foundation which supports the Kidney Cancer Association. More information can be found in the full news story below.
The fast track designation is designed to expedite the review process for treatments of fatal diseases that do not already have viable alternatives for treatment. With the designation, cabozantinib is now also eligible for a Priority Review of a New Drug Application.
Imagine the devastation of learning you have cancer, and then imagine being told it has advanced and already spread to other areas of your body
The purpose of this investigational study is to better understand how vandetanib affects humans who have kidney cancer related to von Hippel-Lindau (VHL) disease, and to develop tests that may improve researchers understanding of kidney cancer and its effects.
Learn some basic facts about kidney cancer and how it is treated in this brief, informative, video provided by Novartis, a pharmaceutical company.
Right now, most cancer patients only have a few options for treatment. They can get chemotherapy or radiation in order to kill bad cells and stop them from dividing, and they can get surgery to cut out the disease.
More Americans are surviving childhood cancers than ever before, but many suffer lingering health problems as adults, a new study finds.
Cabozantinib is also in 45 ongoing or planned clinical trials, including pivotal Phase 3 trials in metastatic renal cell cancer (mRCC) in METEOR and advanced hepatocellular cancer (CELESTIAL).
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces...
Older people who need a kidney transplant are better off receiving an available organ from an older deceased donor rather than waiting for one from a younger donor, a new study shows.
|Powered by NeonCRM|